Aurora Cannabis Shares Jump 18% on Convertible Notes Repurchase
By Adriano Marchese
Aurora Cannabis shares jumped in early trading Monday after the company said that it has repurchased 12.3 million Canadian dollars ($9 million) worth of its convertible senior notes to reach positive cash flow targets next year.
At 9:36 a.m. ET, shares were trading more than 18% higher at C$0.85.
The Canadian cannabis company said it has repurchased the principal amount of its convertible senior notes through multiple transactions between mid-August and Friday.
Aurora said the decision to reduce its debt also was to help reduce its annual cash interest costs as it seeks to reach a target of positive cash flow next year. From this transaction, it expects to save about C$660,000 in annualized interest payments.
The amount includes accrued interest, and was satisfied through the issue of 20.1 million of its common shares.
Aurora said it has about C$53 million of notes outstanding.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 11, 2023 09:59 ET (13:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track